Amino Acids for Sarcopenia

(BOOST_CKD Trial)

This trial examines whether specific amino acids can help individuals with advanced kidney disease improve muscle mass and strength. It targets those who struggle to build muscle due to a necessary low-protein diet for kidney health. The study will test valine and a mix of essential amino acids (EEA) to determine which is more effective. This trial may suit individuals with advanced kidney disease who are not on dialysis, experience muscle weakness, and can adhere to a set diet and lifestyle. As an Early Phase 1 trial, the research aims to understand how these amino acids function in people, offering participants the opportunity to explore new treatment possibilities.

The trial does not specify if you need to stop taking your current medications. However, if you are on an SGLT2-i or GLP-1 agonist, you should be on a stable dose for at least 3 months before joining the study, with no dose changes expected in the next 4 months.

Research has shown that valine, a type of amino acid, offers health benefits in several studies. In animal studies, valine extended lifespan. However, limited information exists about its safety for humans with sarcopenia, which involves muscle loss.

Studies on essential amino acids (EAAs) suggest they can improve muscle strength and mass, offering hope for those with sarcopenia. EAAs have been used in various contexts with positive results and no major safety issues reported so far.

Researchers are excited about these treatments for sarcopenia because they harness the power of amino acids, which are the building blocks of protein, essential for muscle health. Unlike standard treatments that might focus on exercise or hormone therapy, the investigational treatments use Valine and essential amino acids (EAA) to directly support muscle growth and repair. Valine offers a targeted approach with a smaller, easily managed dosage (2 g daily), while the EAA treatment provides a broader spectrum of amino acids, including branched-chain amino acids (BCAAs), delivering a robust 20 g daily. This dual approach could offer a promising new pathway to combat muscle loss more effectively and efficiently.

Research has shown that higher levels of valine, a type of amino acid, link to a 47% lower risk of developing sarcopenia, which involves the loss of muscle mass and strength. Valine also aids in energy production and may protect muscles from damage. In this trial, one group of participants will receive valine. Additionally, essential amino acids (EEA) have shown promise in boosting muscle strength and lean body mass in older adults. Studies have found that consuming more EEA links to stronger muscles and better muscle health. Another group in this trial will receive EEA. Overall, both valine and EEA may support muscle health and reduce the effects of sarcopenia.²³⁴⁵⁶